Turning a blind eye to deferasirox's toxicity?

The Lancet

Volumn 381, Issue 9873, 2013, Pages 1183-1184

  Kontoghiorghes, G J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE;

CANCER PATIENT; CARDIOVASCULAR DISEASE; CHELATION THERAPY; DRUG FATALITY; DRUG INDUSTRY; DRUG SAFETY; HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD; LETTER; MEDICAL SOCIETY; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SICKLE CELL ANEMIA; THALASSEMIA; TREATMENT CONTRAINDICATION; UNSPECIFIED SIDE EFFECT;

EID: 84875846874     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60799-0     Document Type: Letter

References (5)

1. Pocock N. CHMP recommends extension of therapeutic indications for deferasirox (Exjade®). http://www.nelm.nhs.uk/en/NeLM-Area/News/2012- November/19/CHMP-recommends-extension-of-therapeutic-indications-for- deferasirox-Exjade-/ (accessed March 20, 2013).
2. Anon. Exjade side effects in real world: a study of 17,764 patients. http://www.ehealthme.com/q/exjade-side-effects-drug-interactions (accessed March 20, 2013).
3. Pocock N. CHMP finalises review of deaths associated with deferasirox (Exjade®) in the US and updates to the SPC. http://www.nelm.nhs.uk/en/NeLM- Area/News/2009-November/02/CHMP-finalises-review-of-deaths-associated-with- deferasirox-Exjade-in-the-US-and-updates-to-the-SPC-/ (accessed March 20, 2013).
4. Anon. List of reactions reported by people who where taking Exjade: 2474 reported reactions. http://www.fda-reports.com/exjade/reaction/death/page1.html (accessed March 20, 2013).
5. Kontoghiorghes GJ, Kolnagou A, Peng CT, Shah SV, Aessopos A. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf 2010; 9: 201-06.